2018
Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility
Huntington S, Zhu W, Hoag J, Wang R, Zeidan A, Giri S, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A. Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility. Blood 2018, 132: 3538. DOI: 10.1182/blood-2018-99-115140.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaConsensus guidelinesFollicular lymphomaPET scansClinical utilityMedicare beneficiariesSetting of CLLEnd Results-Medicare dataPopulation-based cohort studyLarge B-cell lymphomaLow-value imagingLymphoma-directed therapyFirst-line therapyPatients' sociodemographic characteristicsElixhauser Comorbidity IndexPositron emission tomography useYears of treatmentLow clinical utilityLymphoma settingPet ownershipB-cell lymphomaHierarchical multivariable modelUse of PETTreating oncologistComorbidity index
2014
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
Zahr A, Aldin E, Komrokji RS, Zeidan AM. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. Journal Of Blood Medicine 2014, Volume 6: 1-16. PMID: 25565910, PMCID: PMC4278786, DOI: 10.2147/jbm.s50482.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMyelodysplastic syndromeClinical trialsClinical utilityRed blood cell transfusion requirementsLower-risk myelodysplastic syndromesHigh-risk myelodysplastic syndromeActivity of lenalidomideDifferent prognostic scoresMajor clinical trialsPeripheral blood cytopeniasEfficacy of lenalidomideClonal hematopoietic disordersQuality of lifeMechanism of actionMDS managementTransfusion requirementsBlood cytopeniasPrognostic scoreClinical outcomesRisk stratificationMechanisms of resistanceIneffective hematopoiesisLenalidomideDrug lenalidomideLeukemic transformation